 |
33 Diseases |  |
7 Trials |
|
7 Trials |  |
223 News |  |
| «1234 |
- Trial primary completion date: Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction (clinicaltrials.gov) - Feb 12, 2017
P=N/A, N=130, Active, not recruiting, Sponsor: Juntendo University
Trial primary completion date: Apr 2017 --> Jan 2017
- New trial: Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction (clinicaltrials.gov) - Jan 13, 2017
P=N/A, N=130, Active, not recruiting, Sponsor: Juntendo University
- | lurasidone / Generic mfg.
Trial completion: Lurasidone Effects on Tissue Glutamate in Schizophrenia (clinicaltrials.gov) - Dec 29, 2016
P4, N=50, Completed, Sponsor: University of Texas Southwestern Medical Center
Trial primary completion date: Apr 2017 --> Jan 2017 Active, not recruiting --> Completed
- lithium carbonate ER / Generic mfg.
New trial, HEOR: Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies (clinicaltrials.gov) - Sep 8, 2016
P=N/A, N=1000000, Not yet recruiting, Sponsor: University of New Mexico
- || Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical: DREaM: A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (clinicaltrials.gov) - Aug 5, 2016
P3, N=275, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
Active, not recruiting --> Completed Phase classification: P4 --> P3
- perphenazine / Generic mfg.
New P1/2 trial: Evaluation of D3 Receptor Occupancy Using FLUORTRIOPRIDE ([18F]FTP) PET/CT (clinicaltrials.gov) - Jun 28, 2016
P1/2, N=30, Recruiting, Sponsor: University of Pennsylvania
- Enrollment closed: APIC: Antipsychotic Induced Structural and Functional Brain Changes (clinicaltrials.gov) - Jun 10, 2016
P4, N=574, Active, not recruiting, Sponsor: RWTH Aachen University
Phase classification: P4 --> P3 Recruiting --> Active, not recruiting
- | lurasidone / Generic mfg.
Enrollment closed, Enrollment change: Lurasidone Effects on Tissue Glutamate in Schizophrenia (clinicaltrials.gov) - May 17, 2016
P4, N=50, Active, not recruiting, Sponsor: University of Texas Southwestern Medical Center
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | N=32 --> 50
- Clopixol (zuclopenthixol) / Lundbeck, Serlect (sertindole) / Lundbeck, Abbott
Enrollment closed, Trial primary completion date: Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients (clinicaltrials.gov) - Mar 1, 2016
P4, N=25, Active, not recruiting, Sponsor: Technische Universität München
Recruiting --> Active, not recruiting | N=32 --> 50 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> May 2016
- Enrollment open: APIC: Antipsychotic Induced Structural and Functional Brain Changes (clinicaltrials.gov) - Nov 21, 2015
P4, N=666, Recruiting, Sponsor: RWTH Aachen University
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2016 --> May 2016 Not yet recruiting --> Recruiting
- ||||| New trial: Family Intervention in Recent Onset Schizophrenia Treatment (FIRST) (clinicaltrials.gov) - Nov 9, 2015
P4, N=300, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
- Clopixol (zuclopenthixol) / Lundbeck
New trial: Antipsychotics and Risk of Hyperglycemic Emergencies (clinicaltrials.gov) - Oct 22, 2015
P=N/A, N=725489, Completed, Sponsor: Canadian Network for Observational Drug Effect Studies, CNODES
- |||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Enrollment open: DREaM: A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (clinicaltrials.gov) - Jul 16, 2015
P4, N=275, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- lurasidone / Generic mfg.
Trial primary completion date: Lurasidone Effects on Tissue Glutamate in Schizophrenia (clinicaltrials.gov) - Jun 11, 2015
P4, N=32, Recruiting, Sponsor: University of Texas Southwestern Medical Center
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2014 --> Jun 2016
- | Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical: DREaM: A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (clinicaltrials.gov) - Jun 9, 2015
P4, N=275, Not yet recruiting, Sponsor: Janssen Scientific Affairs, LLC
Trial primary completion date: Dec 2014 --> Jun 2016 Phase classification: P3 --> P4
- | New P4 trial: APIC: Antipsychotic Induced Structural and Functional Brain Changes (clinicaltrials.gov) - May 7, 2015
P4, N=666, Not yet recruiting, Sponsor: RWTH Aachen University
- |||||||||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J, Invega Trinza (paliperidone palmitate extended-release 3-month injection) / J&J
Clinical: DREaM: A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform (clinicaltrials.gov) - May 1, 2015
P3, N=275, Not yet recruiting, Sponsor: Janssen Scientific Affairs, LLC
- |||||||||| New P3 trial, Adverse events: Pharmacovigilance in Gerontopsychiatric Patients (clinicaltrials.gov) - Mar 2, 2015
P3, N=2000, Recruiting, Sponsor: Hannover Medical School
- | Clopixol (zuclopenthixol) / Lundbeck, Serlect (sertindole) / Lundbeck, Abbott
New P4 trial: Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients (clinicaltrials.gov) - Dec 5, 2014
P4, N=25, Recruiting, Sponsor: Technische Universität München
- lurasidone / Generic mfg.
New P4 trial: Lurasidone Effects on Tissue Glutamate in Schizophrenia (clinicaltrials.gov) - Jul 24, 2014
P4, N=32, Recruiting, Sponsor: University of Texas Southwestern Medical Center
- Clinical: A Randomized Double-blind Trial With 6 Antipsychotic Drugs for Schizophrenia (clinicaltrials.gov) - Jul 17, 2014
P=N/A, N=550, Completed, Sponsor: Beijing Hui-Long-Guan Hospital
- Trial primary completion date: IMPACT: Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics (clinicaltrials.gov) - May 14, 2014
P4, N=127, Completed, Sponsor: Johns Hopkins University
Phase classification: P3 --> P4 Trial primary completion date: Oct 2013 --> Mar 2014
- Trial completion date: IMPACT: Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics (clinicaltrials.gov) - May 14, 2014
P4, N=127, Completed, Sponsor: Johns Hopkins University
Trial primary completion date: Oct 2013 --> Mar 2014 Trial completion date: Apr 2014 --> Mar 2014
- Trial completion: IMPACT: Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics (clinicaltrials.gov) - May 14, 2014
P4, N=127, Completed, Sponsor: Johns Hopkins University
Trial completion date: Apr 2014 --> Mar 2014 Recruiting --> Completed
- |||| Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Trial completion: 15 Month Study for Adults Who Have Been Diagnosed With Schizophrenia and Incarcerated (clinicaltrials.gov) - Feb 2, 2014
P4, N=453, Completed, Sponsor: Janssen Scientific Affairs, LLC
Recruiting --> Completed Active, not recruiting --> Completed
- Invega Sustenna (paliperidone palmitate extended-release 1-month injection) / J&J
Enrollment change: Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital (clinicaltrials.gov) - Jul 3, 2013
P4, N=0, Withdrawn, Sponsor: Ortho-McNeil Janssen Scientific Affairs, LLC
Active, not recruiting --> Completed N=1000 --> 0
- Enrollment change: COATS: Comparison of Optimal Antipsychotic Treatments for Adults With Schizophrenia (clinicaltrials.gov) - Jan 2, 2013
P4, N=21, Completed, Sponsor: National Institute of Mental Health (NIMH)
N=1000 --> 0 N=60 --> 21
- perphenazine / Generic mfg., olanzapine / Generic mfg.
Trial termination: Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia (clinicaltrials.gov) - Sep 16, 2012
P=N/A, N=8, Terminated, Sponsor: VA Nebraska Western Iowa Health Care System
N=60 --> 21 Recruiting --> Terminated; Low enrollment rate.
- perphenazine / Generic mfg., olanzapine / Generic mfg.
Enrollment change: Decision Aid to Facilitate Shared Decision Making During Treatment in Schizophrenia (clinicaltrials.gov) - Sep 16, 2012
P=N/A, N=8, Terminated, Sponsor: VA Nebraska Western Iowa Health Care System
Recruiting --> Terminated; Low enrollment rate. N=100 --> 8
- Enrollment change: IMPACT: Reducing Weight Gain and Improving Metabolic Function in Children Being Treated With Antipsychotics (clinicaltrials.gov) - Apr 19, 2012
P4, N=132, Recruiting, Sponsor: Johns Hopkins University
N=100 --> 8 N=240 --> 132